Fulgent Genetics (FLGT) Cost of Revenue (2015 - 2026)

Fulgent Genetics has disclosed Cost of Revenue across 12 years of filings, most recently posting $49.6 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $49.6 million, up 10.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $269.9 million (up 8511.81% YoY), and the FY2025 annual result was $191.8 million, up 429.15% from the prior year.
• Cost of Revenue came in at $49.6 million for Q1 2026 at Fulgent Genetics, down from $159.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $159.4 million in Q4 2025 to a low of -$95.6 million in Q4 2024.
• The 5-year median for Cost of Revenue is $12.3 million (2025), against an average of $29.6 million.
• Across the five-year window, Cost of Revenue jumped 1452.02% in 2022 and tumbled 311.25% in 2024, its largest moves.
• Fulgent Genetics' Cost of Revenue stood at $10.3 million in 2022, then surged by 341.59% to $45.3 million in 2023, then tumbled by 311.25% to -$95.6 million in 2024, then soared by 266.66% to $159.4 million in 2025, then plunged by 68.85% to $49.6 million in 2026.
• The last three Cost of Revenue figures came in at $49.6 million (Q1 2026), $159.4 million (Q4 2025), and $48.6 million (Q3 2025), per Business Quant data.